Alan Jenkins is an experienced leader in the Pharmaceutical Industry, having spent more than 20 years developing innovative new therapies for patients. Alan is a Director, Global Program Leader at Janssen Research & Development (Johnson & Johnson) where he leads global clinical operations teams responsible for delivering a portfolio of early and late development assets. Prior to joining Janssen he worked in Clinical Development & Medical Affairs at Novartis Pharmaceuticals. His therapeutic area experience includes Rare Diseases, Ophthalmic, Retinal, Cardiovascular, Pulmonary Hypertension, Renal, Metabolics, Diabetes, Obesity, Liver Disease, Endocrine, Infectious Diseases, Neuroscience, and Psychiatry.
Alan holds a B.A. from Bates College (magna cum laude), an M.B.A. from Columbia University, and serves as an advisor for the Transformative Leadership in Disruptive Times program at the Stillman School of Business at Seton Hall University.